This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/domain/vavai/projekt/
n13http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n11http://linked.opendata.cz/resource/domain/vavai/subjekt/
n10http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n19http://bibframe.org/vocab/
n18http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F26475821%3A_____%2F13%3A%230000174%21RIV14-MZ0-26475821/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F26475821%3A_____%2F13%3A%230000174%21RIV14-MZ0-26475821
rdf:type
skos:Concept n10:Vysledek
rdfs:seeAlso
http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=3513&category_id=102&option=com_virtuemart
dcterms:description
Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor. Clinical trials have shown its efficacy in advanced non-small cell lung cancer (NSCLC). We conducted a large retrospective study based on clinical experience aiming to prove erlotinib's efficacy and safety in patients with advanced-stage squamous cell NSCLC. Totally 375 patients with advanced-stage (IIIB, IV) squamous cell NSCLC were treated with erlotinib. Erlotinib was continued until disease progression or intolerable toxicity. 1 (0.3%) complete response (CR), 28 (7.5%) partial responses (PR) and 198 (52.8%) stable diseases (SD) were achieved. Overall response rate (ORR) and disease control rate (DCR) were 7.8% and 60.5%, respectively. Median progression-free survival (PFS) was 3.0 months and median overall survival (OS) was 7.6 months. PFS of patients with CR/PR, SD and PD were 7.6, 3.9 and 1.0 months, respectively (P<0.001). OS of patients with CR/PR, SD and PD were 13.3, 10.9 and 3.8 months, respectively (P<0.001).The most common adverse effects were rash and diarrhoea. In conclusion ertlotinib is effective and well-tolerated in patients with advanced-stage squamous cell NSCLC. Erlotinib is an epidermal growth factor receptor tyrosine-kinase inhibitor. Clinical trials have shown its efficacy in advanced non-small cell lung cancer (NSCLC). We conducted a large retrospective study based on clinical experience aiming to prove erlotinib's efficacy and safety in patients with advanced-stage squamous cell NSCLC. Totally 375 patients with advanced-stage (IIIB, IV) squamous cell NSCLC were treated with erlotinib. Erlotinib was continued until disease progression or intolerable toxicity. 1 (0.3%) complete response (CR), 28 (7.5%) partial responses (PR) and 198 (52.8%) stable diseases (SD) were achieved. Overall response rate (ORR) and disease control rate (DCR) were 7.8% and 60.5%, respectively. Median progression-free survival (PFS) was 3.0 months and median overall survival (OS) was 7.6 months. PFS of patients with CR/PR, SD and PD were 7.6, 3.9 and 1.0 months, respectively (P<0.001). OS of patients with CR/PR, SD and PD were 13.3, 10.9 and 3.8 months, respectively (P<0.001).The most common adverse effects were rash and diarrhoea. In conclusion ertlotinib is effective and well-tolerated in patients with advanced-stage squamous cell NSCLC.
dcterms:title
Erlotinib in the treatment of advanced squamous cell NSCLC Erlotinib in the treatment of advanced squamous cell NSCLC
skos:prefLabel
Erlotinib in the treatment of advanced squamous cell NSCLC Erlotinib in the treatment of advanced squamous cell NSCLC
skos:notation
RIV/26475821:_____/13:#0000174!RIV14-MZ0-26475821
n10:predkladatel
n11:ico%3A26475821
n4:aktivita
n8:V n8:P n8:I
n4:aktivity
I, P(NR9087), V
n4:cisloPeriodika
6
n4:dodaniDat
n7:2014
n4:domaciTvurceVysledku
n13:2689677 n13:6636365
n4:druhVysledku
n15:J
n4:duvernostUdaju
n5:S
n4:entitaPredkladatele
n18:predkladatel
n4:idSjednocenehoVysledku
73177
n4:idVysledku
RIV/26475821:_____/13:#0000174
n4:jazykVysledku
n14:eng
n4:klicovaSlova
squamous cell, NSCLC, erlotinib, targeted treatment, EGFR-TKI
n4:klicoveSlovo
n12:squamous%20cell n12:erlotinib n12:EGFR-TKI n12:targeted%20treatment n12:NSCLC
n4:kodStatuVydavatele
SK - Slovenská republika
n4:kontrolniKodProRIV
[E7447A7028F5]
n4:nazevZdroje
Neoplasma
n4:obor
n9:EB
n4:pocetDomacichTvurcuVysledku
2
n4:pocetTvurcuVysledku
10
n4:projekt
n16:NR9087
n4:rokUplatneniVysledku
n7:2013
n4:svazekPeriodika
60
n4:tvurceVysledku
Minárik, Marek Benešová, Lucie
s:issn
0028-2685
s:numberOfPages
7
n19:doi
10.4149/neo_2013_086